A new blood-testing test could reduce the number of false positive results for diseases such as hemophilia according to European Commission members who returned a proposal for the practical analysis of the results downloaded by the IT Clearinghouse.

Organisations such as the IT Clearinghouse are aiming to reach a total of 10 million people through quick grants for diseases. We are working on medium- and high-risk levels for the project and are aiming at a total of 36 million said the commission president Urs van der Does.

The findings which were presented today at a virtual EU clearinghouse event in Brussels show that the current screening technology for blood disorders in several possible scenarios from the laboratory to the pharmacy are effective when implemented on a regional (Low payer) scale.

It also shows that the technology can work with other screening tests as well as tests that involve thrombolytic (an artificial non-anticoagulant) blood products. It means that this test can be used without having to understand the traditional blood tests – which requires a lot of technical expertise expertise that we are up against in programmes that run over the course of a year said Justin Moro IT Clearinghouses chief executive.

A IT Clearinghouse proposal summary together with other initial findings were presented to the IT Clearinghouse by Belgium Germany and Luxembourg.

With the plan summaries and accompanying information IT Clearinghouse members will vote on whether the technique is discretionary and is implemented on a high-risk basis. If it is the approach gives the IT Clearinghouse members a way to offer it to several million people.

When tested on a group of similar population size with a biophysical blood test (i.e. kidney function) the new technology is superior to the other three methods tested but not as good at reducing false positives as the other methods. Also less effective for clinicians.